Abstract Library

#4363 61Cu-NODAGA-LM3 for the detection of neuroendocrine tumours: Preliminary results of the COPPER PET in NET trial, a randomised, crossover, readers blind, phase I/II non-inferiority study

Introduction: Currently approved PET tracers, Gallium-68 or Copper-64 labelled somatostatin receptor (SST) agonists (NETSPOT®, SOMAKIT® and Detecnet™), for imaging well-differentiated gastroenteropancreatic and bronchopulmonary neuroendocrine tumours (NET) have limitations. Radiolabelled SST antagonists offer superior imaging properties over agonists, and the combination with Copper-61, an unexplored PET isotope with a 3.33-hour half-life and favourable production characteristics, could be promising.

Conference:

Presenting Author: Nicolas G

Authors: Nicolas G, Chirindel A, Kaul F, Rommers N, Johayem A,

Keywords: Somatostatin Receptor PET/CT, Well-differentiated NEN, gastroenteropancreatic NET, bronchopulmonary NET, randomised controlled clinical trial, somatostatin receptor antagonist,

#4031 68-Gallium DOTANOC PET/CT pitfall in adnexal tumor

Introduction: PET/CT with 68Ga-DOTA is a commonly used tool in the baseline evaluation and follow-up of NETs due to its high specificity and sensitivity, showing better performance than CT in detecting primary and metastatic disease. However, we must know more about its normal physiological distribution, its variation in pathologies, and the possibility of confusion with benign processes to optimize its interpretation.

Conference:

Presenting Author:

Authors: González Devia D, Chaar-Lugo A, Rojas-Camacho J, Londoño-Schimmer E, Buriticá-Cifuentes C,

Keywords: Neuroendocrine tumor, 68Ga-DOTANOC, PET/CT, Rectal neuroendocrine tumor, Adnexal tumor, Pitfalls,

#3890 Intracardiac metastasis in well-differentiated ileal neuroendocrine tumor

Introduction: About 60% of well-differentiated neuroendocrine tumors are diagnosed with metastatic disease, above all with liver involvement. The incidence of myocardial metastasis in patients with metastatic neuroendocrine tumor is less than 4%. These are mostly asymptomatic metastasis, so the diagnosis is often incidental.

Conference:

Presenting Author: Della Torre S

Authors: Della Torre S, Smiroldo V, Cozzi C, Galeassi A, Di Bella S,

Keywords: cardiac metastasis, neuroendocrine tumor,

#3693 Gallium-68 DOTANOC PET/CT in locally advanced/metastatic WHO grade 2 gastroenteropancreatic neuroendocrine tumors – Clinical and prognostic impact in assessing progression free survival

Introduction: Ga-68 DOTANOC PET/CT based prognostic factors can help in risk-stratification of patients with locally advanced/metastatic GEP-NETs.

Conference:

Presenting Author:

Authors: Dev I, Rangarajan V, Purandare N, Agrawal A, Shah S,

Keywords: Ga-68 DOTANOC, PET/CT, Grade 2 NET, SUVmax, liver involvement,

#2794 Pancreatic Neuroendocrine Tumor (pNET) Showing Remission after Tuberculostatic Treatment – An Unusual Case Report Suggesting Anti-Proliferative Effects of Antibiotics in pNETs

Introduction: Several classes of antibiotics have been associated with anti-proliferative effects on cancer cells; however, there is no data on this regarding pNETs.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Kiesewetter B

Authors: Kiesewetter B, Lagler H, Mazal P, Kretschmer-Chott E, Haug A,

Keywords: pancreatic neuroendocrine tumors, treatment, somatostatin analogs, antibiotics, lanreotide,